Page last updated: 2024-10-28

hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester and Congenital Zika Syndrome

hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester has been researched along with Congenital Zika Syndrome in 1 studies

hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester : An organic phosphonate that is the trisacetoxymethylester derivative of naphthalene substituted hydroxymethylphosphonic acid. It has been found to inhibit insulin receptor tyrosine kinase activity and insulin stimulated glucose oxidation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W1
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1

Other Studies

1 other study available for hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester and Congenital Zika Syndrome

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020